{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T03:29:43Z","timestamp":1768793383019,"version":"3.49.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p>Specific and high-quality evidence on the efficacy of the current targeted therapies for axial disease in psoriatic arthritis (axPsA) is still scarce. Indeed, almost all the cohorts investigated in clinical trials on PsA consisted of patients with peripheral arthritis, where a small number of them also had axial involvement. Only one randomized controlled trial was so far specifically designed to assess the efficacy of a biological disease-modifying antirheumatic drug (DMARD) in axPsA. For other biological and synthetic targeted DMARDs, the most specific evidence for treatment in axPsA is extrapolated from<jats:italic>post-hoc<\/jats:italic>analyses based on PsA patients with concomitant peripheral and axial manifestations. Furthermore, the current trials and<jats:italic>post-hoc<\/jats:italic>analysis on axPsA are affected by major limitations, including the lack of a widely accepted definition of axPsA and the lack of specific and validated outcome measures. Finally, poor data are available on the genetics of axPsA, although alleles differentially expressed in different patterns of axPsA might offer advantages in the prospective of personalized medicine in axPsA patients. Overall, this review suggests that there is an urgent need for more reliable evidence derived from studies specifically designed for axPsA and based on a validated definition of axPsA and on specific outcome measures.<\/jats:p>","DOI":"10.3389\/fgene.2021.689984","type":"journal-article","created":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T05:05:39Z","timestamp":1624856739000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeted Therapies in Axial Psoriatic Arthritis"],"prefix":"10.3389","volume":"12","author":[{"given":"Alberto","family":"Floris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattia","family":"Congia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Chessa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Maddalena","family":"Angioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Piga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Cauli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","article-title":"Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial","volume":"80","author":"Baraliakos","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3899\/jrheum.150641","article-title":"New approaches in tumor necrosis factor antagonism for the treatment of psoriatic arthritis: certolizumab pegol","volume":"93","author":"Cauli","year":"2015","journal-title":"J. Rheumatol. Suppl."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.3899\/jrheum.090412","article-title":"Axial psoriatic arthritis: update on a longterm prospective study","volume":"36","author":"Chandran","year":"2009","journal-title":"J. Rheumatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/art.41477","article-title":"Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study","volume":"73","author":"Deodhar","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"","journal-title":"Arthritis Rheumatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/S0140-6736(18)30952-8","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"391","author":"Deodhar","year":"2018","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/annrheumdis-2020-eular.1448","article-title":"Fri0271 impact of Hla-B27 status on clinical outcomes among patients with ankylosing spondylitis treated with secukinumab","volume":"79","author":"Deodhar","year":"","journal-title":"Ann. Rheum. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1136\/annrheumdis-2019-eular.1235","article-title":"Ab0744 efficacy of ixekizumab in active psoriatic arthritis (psa) patients with axial pain starting before age 45: a subgroup analysis of spirit-P1 and spirit-P2 phase 3 clinical trials","volume":"78","author":"Deodhar","year":"","journal-title":"Ann. Rheum. Dis."},{"key":"B14","unstructured":"Efficacy and safety of upadacitinib in patients with psoriatic arthritis and axial involvement [abstract] DeodharA. RanzaR. GanzF. GaoT. AndersonJ. \u00d6st\u00f6rA. Arthritis Rheumatol72"},{"key":"B15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","article-title":"Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)","volume":"79","author":"Dougados","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41584-018-0006-8","article-title":"Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison","volume":"14","author":"Feld","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/annrheumdis-2020-eular.1229","article-title":"Op0223 efficacy and safety of upadacitinib in patients with active psoriatic arthritis and inadequate response to biologic disease-modifying anti-rheumatic drugs (select-Psa-2): a double-blind, randomized controlled phase 3 trial","volume":"79","author":"Genovese","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"B19","first-page":"1040","article-title":"Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy","volume":"34","author":"Genovese","year":"2007","journal-title":"J. Rheumatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s11926-007-0074-2","article-title":"Axial disease in psoriatic arthritis","volume":"9","author":"Gladman","year":"2007","journal-title":"Curr. Rheumatol. Rep."},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.201672","article-title":"Updates on axial psoriatic arthritis from the 2020 GRAPPA annual meeting","volume-title":"J. Rheumatol.","author":"Gladman","year":"2021"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","article-title":"European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies","volume":"71","author":"Gossec","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1002\/art.23606","article-title":"Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two","volume":"58","author":"Haibel","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/annrheumdis-2020-eular.474","article-title":"Op0054 efficacy of guselkumab, a monoclonal antibody that specifically binds to the P19-subunit of Il-23, on endpoints related to axial involvement in patients with active Psa with imaging-confirmed sacroiliitis: week-24 results from two phase 3, randomized, double-blind, placebo-controlled studies","volume":"79","author":"Helliwell","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1136\/annrheumdis-2016-209853","article-title":"Axial disease in psoriatic arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis","volume":"76","author":"Jadon","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor \u03b1 antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four\u2013week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1136\/annrheumdis-2015-209068","article-title":"Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1\/PSUMMIT-2)","volume":"75","author":"Kavanaugh","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1093\/rheumatology\/key104","article-title":"Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients","volume":"57","author":"Maksymowych","year":"2018","journal-title":"Rheumatology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e000017","DOI":"10.1136\/rmdopen-2014-000017","article-title":"Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis","volume":"1","author":"Maneiro","year":"2015","journal-title":"RMD Open"},{"key":"B31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/annrheumdis-2020-eular.6727","article-title":"LB0001 Efficacy and safety of upadacitinib versus placebo and adalimumab in patients with active psoriatic arthritis and inadequate response to non-biologic disease-modifying anti-rheumatic drugs (SELECT-PsA-1): a double-blind, randomized controlled phase 3 trial","volume":"79","author":"Mcinnes","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"","journal-title":"Lancet"},{"key":"B34","first-page":"4140","article-title":"Efficacy and Safety of Deucravacitinib (BMS-986165), an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: results from a phase 2, randomized, double-blind, placebo-controlled trial","volume":"72","author":"Mease","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B37","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1136\/annrheumdis-2019-216835","article-title":"Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials","volume":"80","author":"Mease","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1136\/annrheumdis-2018-eular.2140","article-title":"OP0307 efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial","volume":"77","author":"Mease","year":"","journal-title":"Ann. Rheum. Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled, and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Semin. Arthritis Rheum."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"B44","first-page":"728","article-title":"Response to treatment with ixekizumab in patients with active non-radiographic axial spondyloarthritis based on HLA-B27 status and disease duration","volume":"72","author":"Navarro-Comp\u00e1n","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/acr2.11102","article-title":"Secukinumab 150\/300 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 3-year results from the phase 3 MEASURE 3 study","volume":"2","author":"Pavelka","year":"2020","journal-title":"ACR Open Rheumatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11926-020-0886-x","article-title":"Complexities in genetics of psoriatic arthritis","volume":"22","author":"Rahmati","year":"2020","journal-title":"Curr. Rheumatol. Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/acr.23789","article-title":"2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/art.23471","article-title":"Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept","volume":"58","author":"van der Heijde","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1093\/rheumatology\/kez420","article-title":"Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5","volume":"59","author":"van der Heijde","year":"2020","journal-title":"Rheumatology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"key":"B53","doi-asserted-by":"publisher","first-page":"596086","DOI":"10.3389\/fimmu.2020.596086","article-title":"The IL-17\/IL-23 axis and its genetic contribution to psoriatic arthritis","volume":"11","author":"Vecellio","year":"2021","journal-title":"Front. Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.clim.2016.07.019","article-title":"Implications of the diversity of class I HLA associations in psoriatic arthritis","volume":"172","author":"Winchester","year":"2016","journal-title":"Clin. Immunol."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2021.689984\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T17:59:40Z","timestamp":1672595980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2021.689984\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,28]]},"references-count":54,"alternative-id":["10.3389\/fgene.2021.689984"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2021.689984","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,28]]},"article-number":"689984"}}